GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Mereo BioPharma Group MREO · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.30

+4.28%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2024

Revenue

—

FY2015FY2024

Net income

−$43.3m

FY2015FY2024

Free cash flow

−$33.5m

FY2015FY2024

Shareholders' equity

$61.0m

FY2015FY2024

Income statement

Fiscal years

FY2024FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Revenue——$50.1m——————
Gross profit—$1.2m$25.5m——————
Research and development$20.9m$30.8m$32.4m$21.0m$30.1m$30.3m$34.6m$24.6m$5.5m
Operating income−$47.4m−$53.7m−$28.8m−$48.2m−$50.4m−$46.0m−$45.3m−$36.2m−$13.1m
Net income−$43.3m−$42.1m$17.5m−$209.8m−$44.5m−$42.7m−$38.8m−$28.4m−$12.2m
Diluted earnings per share-0.06-0.070.03-0.62-0.50-0.60-0.56-0.63-0.19

Balance sheet

At each fiscal year end

FY2024FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Total assets$76.4m$106.5m$165.1m$86.1m$114.6m$67.3m$96.3m$86.8m$39.9m
Cash and short-term investments$69.8m$68.1m$127.6m$32.1m$21.7m$27.5m$52.5m$53.6m$12.3m
Total liabilities$15.4m$31.7m$46.4m$106.5m$61.2m$34.5m$33.9m$7.5m$4.1m
Debt$5.5m$15.5m$22.7m$24.5m$43.0m$21.5m$20.8m$3.1m—
Shareholders' equity$61.0m$74.8m$118.7m−$20.5m$53.4m$32.8m$62.5m$79.3m$35.7m
Shares outstanding740m603m528m339m89m71m69m45m64m

Cash flow

Fiscal years

FY2024FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Cash from operations−$32.8m−$47.8m−$7.2m−$36.3m−$58.6m−$23.1m−$32.1m−$29.7m−$6.7m
Capital spending−$699,000−$12,300−$735,700−$20,500−$26,800−$40,000−$2.3m—−$220,000
Free cash flow−$33.5m−$47.8m−$7.9m−$36.4m−$58.6m−$23.2m−$34.4m−$29.7m−$6.9m

Latest quarters

By quarter end

Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024Mar 2024Dec 2023
Revenue—$500,000—————$10.0m
Gross profit—$368,000—————$7.4m
Operating income−$10.0m−$10.5m−$11.0m−$15.3m−$9.4m−$12.8m−$9.9m−$28.4m
Net income−$7.0m−$14.6m−$13.0m−$7.0m−$15.0m−$12.3m−$9.0m−$29.5m
Diluted earnings per share-0.01-0.02-0.02-0.01-0.02-0.02-0.01-0.04
Cash from operations−$7.0m−$7.0m−$8.0m−$9.0m−$7.0m−$7.0m−$7.0m−$4.0m
Total assets$53.6m$62.6m$68.3m$76.4m$88.7m$96.1m$55.9m$66.5m
Cash and short-term investments$48.7m$56.1m$62.5m$69.8m$80.5m$87.4m$48.7m$57.4m
Debt———————$4.4m
Shareholders' equity$46.6m$54.2m$60.1m$61.0m$72.5m$78.7m$42.8m$50.5m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income18.1%-1.2%—
Net income—-0.5%—

Valuation history

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019
Price to earnings-34.4-29.7-6.227.7-3.3-3.8
Price to sales—87.6—9.7——

Share price return

Finished calendar years

2025202420232022202120202019
Return1%58%265%-66%-52%174%-80%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.